Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Receives Average Rating of “Hold” from Analysts

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) has been given a consensus rating of “Hold” by the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $17.1667.

A number of brokerages have recently commented on ADIL. Loop Capital set a $6.00 price objective on shares of Adial Pharmaceuticals in a research report on Monday, June 15th. Needham & Company LLC downgraded shares of Adial Pharmaceuticals to a “buy” rating in a research report on Monday, June 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Monday, April 20th. Finally, Brookline Capital Markets cut shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th.

Insider Activity

In related news, major shareholder Coastlands Capital Lp bought 25,000 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were acquired at an average price of $2.60 per share, for a total transaction of $65,000.00. Following the completion of the acquisition, the insider owned 373,322 shares of the company’s stock, valued at approximately $970,637.20. The trade was a 7.18% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.86% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC raised its stake in shares of Adial Pharmaceuticals by 887.3% during the 4th quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock worth $27,000 after purchasing an additional 109,500 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Adial Pharmaceuticals in the 3rd quarter valued at approximately $51,000. Finally, Armistice Capital LLC bought a new position in shares of Adial Pharmaceuticals in the fourth quarter valued at $562,000. Institutional investors and hedge funds own 16.41% of the company’s stock.

Adial Pharmaceuticals Stock Performance

Shares of Adial Pharmaceuticals stock opened at $2.80 on Friday. The business’s 50 day simple moving average is $2.27 and its 200 day simple moving average is $2.97. Adial Pharmaceuticals has a 52-week low of $1.31 and a 52-week high of $18.90. The firm has a market cap of $5.99 million, a PE ratio of -0.35 and a beta of 1.43.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its quarterly earnings results on Friday, May 8th. The company reported ($1.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.73) by $1.25.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.